Philogen Logo

Philogen

Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.

PHIL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005373789 (+1 more)
LEI:
81560009EA1577917768
Country:
Italy
Address:
PIAZZA LA LIZZA, 7, 53100 SIENA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Philogen is a Swiss-Italian biotechnology company, founded in 1996, that develops innovative biopharmaceuticals for the treatment of cancer and other serious conditions. The company is a pioneer in proprietary ligand-based targeting approaches, which use high-affinity antibodies and small molecules to deliver therapeutic agents directly to the site of disease. As a fully-integrated company, its expertise spans from the discovery of novel tumor markers using chemical proteomics to the GMP manufacturing of its targeted therapies, such as immunocytokines and radioligand therapeutics. Philogen's clinical-stage pipeline focuses primarily on oncology indications.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 18:50
Director's Dealing
Allegato 3F
Italian 26.9 KB
2025-10-06 18:15
Transaction in Own Shares
2025 10 06 - CS settimanale acquisto azioni proprie
Italian 294.0 KB
2025-09-29 17:58
Transaction in Own Shares
2025 09 29 - CS settimanale acquisto azioni proprie
Italian 298.0 KB
2025-09-26 12:26
Interim Report
Half Year Report 2025 as of 30.06.2025 (Courtesy English Translation)
English 2.1 MB
2025-09-26 12:24
Interim Report
Relazione Finanziaria Semestrale al 30.06.2025
Italian 2.0 MB
2025-09-23 21:11
Earnings Release
The Board of Directors Approves the Half-Yearly Financial Report at 30 June 202…
English 416.6 KB
2025-09-23 21:10
Interim Report
Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al …
Italian 377.0 KB
2025-09-15 14:52
Transaction in Own Shares
2025 09 15 - CS settimanale acquisto azioni proprie
Italian 184.3 KB
2025-08-18 20:02
M&A Activity
Press Release Clearance e Closing OncoACP3 (Price Sensitive)
Italian 213.9 KB
2025-07-07 16:50
Transaction in Own Shares
2025 07 07 - CS settimanale acquisto azioni proprie
Italian 153.0 KB
2025-07-07 12:08
Director's Dealing
Allegato 3F
Italian 26.7 KB
2025-06-30 17:04
Transaction in Own Shares
2025 06 30 - CS settimanale acquisto azioni proprie
Italian 181.7 KB
2025-06-25 12:29
Legal Proceedings Report
Philogen Provides Update on Marketing Authorization Application for Nidlegy™ in…
English 180.5 KB
2025-06-11 01:34
Regulatory News Service
Press Release Licenza OncoACP3 (Price Sensitive)
Italian 225.0 KB
2025-06-03 13:40
Transaction in Own Shares
2025 06 03 - CS settimanale acquisto azioni proprie
Italian 144.1 KB

Automate Your Workflow. Get a real-time feed of all Philogen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Philogen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.